

There is no advantage for treating patients with myeloid malignancies with a single dose of 6mg/m² of gemtuzumab ozogamicin in combination with induction chemotherapy when compared with a 3mg/m² dose, with respect to response, disease free and survival, either overall, or in any disease subgroup

